ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

B and Plasma Cell Populations Drive Chronic Rejection After Lung Transplantation

M. Bueno1, N. F. Smirnova2, K. Riemondy3, P. Suresh1, M. Brown1, X. Wang1, S. Collins4, J. Sembrat1, M. Koenigshoff1, M. Snyder1, J. McDyer1, O. Eickelberg1

1Pulmonary and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, 2I2MC, INSERM UMR1297, Toulouse, France, 3Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, CO, 4Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO

Meeting: 2022 American Transplant Congress

Abstract number: 576

Keywords: B cells, Fibrosis, Lung transplantation, Rejection

Topic: Basic Science » Basic Clinical Science » 19 - Chronic Organ Rejection

Session Information

Session Name: Chronic Organ Rejection

Session Type: Rapid Fire Oral Abstract

Date: Tuesday, June 7, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 6:20pm-6:30pm

Location: Hynes Room 309

*Purpose: Chronic lung allograft dysfunction (CLAD) remains the major determinant of morbidity and mortality post-lung transplantation (LTx). Bronchiolitis obliterans syndrome (BOS) is the most prevalent presentation of CLAD, but its underlying mechanisms remain poorly understood. We have established a single HLA antigen mismatch model of orthotopic LTx in mice that recapitulates several features of BOS and have identified B cells as major contributors to chronic rejection. However, the extent of B cell heterogeneity and their role in chronic rejection remains unclear.

*Methods: To investigate the specific roles of B and plasma cells in vivo, we performed two different murine models of orthotopic lung transplant (HLA->C57BL/6J and B6D2F1/J->C57BL/6J) and analyzed allografts as well as their syngeneic grafts. To assess the clinical relevance of our findings and their relevance to BOS, we compared explants from patients, who developed BOS and underwent re-transplantation, with healthy controls from retrospective clinical cohorts.

*Results: Our detailed atlas of cell population changes of chronic rejection after LTx in mice showed that Mzb1+ plasma cells (PCs) were the most prominently increased cell population in BOS lungs. In both murine models of lung rejection after LTx, we localized these Mzb1+ PCs populations surrounding the remodeled and obliterated airways, and in areas with dense collagen deposition. In BOS patients, we observed B cell-rich ectopic lymphoid follicles disseminated throughout the lung. Plasma cells, expressing MZB1, were robustly detected in the peribronchial areas in BOS (MZB1+ stained area in BOS 1.24% -vs. 0.16% in donors; p<0.0005), even in the absence of neighboring B cells. Importantly, RNA-sequencing of frozen lung tissue from BOS explants revealed that MZB1 and CXCL13 (encoding a chemokine involved in B cell homing), were amongst the most significantly upregulated genes when compared with control lung samples (increased by 36.50- and 47.10-fold, respectively; p<0.05).

*Conclusions: Our data identify a new role for MZB1+ plasma cells in the pathogenesis of CLAD-associated BOS. These data open an exciting therapeutic approach, in which plasma cells could be specifically targeted to prevent chronic rejection and alleviate tissue remodeling after LTx.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Bueno M, Smirnova NF, Riemondy K, Suresh P, Brown M, Wang X, Collins S, Sembrat J, Koenigshoff M, Snyder M, McDyer J, Eickelberg O. B and Plasma Cell Populations Drive Chronic Rejection After Lung Transplantation [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/b-and-plasma-cell-populations-drive-chronic-rejection-after-lung-transplantation/. Accessed May 28, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences